Amyloid-beta-targeted monoclonal antibodies had negligible effects for adults with mild cognitive impairment or AD-related dementia.

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...

As we age, we all might forget something here or there, but when does it become a concern? Most of us fear Alzheimer’s ...

As people live longer, age-related disorders, including many neurodegenerative diseases, are becoming increasingly common.

Risk for obstructive sleep apnea is 57% higher in adults with cognitive impairment and 65% higher with mild cognitive ...

The review by researchers at Anglia Ruskin University in the UK looked at 30 published studies conducted in cell cultures and ...

A study at Wake Forest University could help get critical answers about Alzheimer’s and genetics, including why data says ...

Please provide your email address to receive an email when new articles are posted on . A similar proportion of patients receiving lithium and patients receiving placebo discontinued their medication.

As of April 2026, more than 40 million GLP-1 receptor agonist prescriptions are dispensed annually in the United States alone ...

There’s a particular kind of unease that settles in slowly. A parent who always had a sharp tongue now just seems detached. A ...

There is a continuum of normal brain-related aging and Alzheimer’s dementia. The in-between state is called mild cognitive ...